ArticleTzu chi medical journal
Evaluating the antidepressant effects of tirzepatide on unpredictable chronic mild stress-induced depression in Swiss Albino mice.
Article in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Depression, diabetes, and obesity often coexist, forming a complex "metabolic-mood syndrome" characterized by inflammation, impaired neuroplasticity, and neuroendocrine dysregulation. Conventional antidepressants show limited efficacy in such cases and may worsen metabolic profiles. Tirzepatide, a dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist approved for diabetes and obesity, may offer neuropsychiatric benefits. The objective of this study was to evaluate its antidepressant-like effects in an unpredictable chronic mild stress (UCMS)-induced depression model of Swiss Albino mice. Materials and Methods: Forty male Swiss Albino mice were randomly divided into five groups ( Results: Duration of immobility was significantly reduced in both FST and TST, in the high-dose group compared to the DC group. Hippocampal BDNF levels were significantly elevated in the high-dose group, suggesting enhanced neuroplasticity. While IL-6 and serotonin levels showed no statistically significant changes, the directional trends point toward possible anti-inflammatory effect and serotonergic modulation. Conclusion: This study provides preclinical evidence for the antidepressant-like effects of tirzepatide, likely mediated through neurotrophic and anti-inflammatory pathways. Tirzepatide holds promise as a novel therapeutic option for managing depression in patients with comorbid metabolic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.